Gregory J. Keir

Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision

Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial

Deep Learning–based Outcome Prediction in Progressive Fibrotic Lung Disease Using High-Resolution Computed Tomography

Biomarker signatures for progressive idiopathic pulmonary fibrosis

The supportive care needs of people living with pulmonary fibrosis and their caregivers: a systematic review

Diagnosis and management of connective tissue disease‐associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand*

Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry

Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF)

Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis

Treatment of idiopathic pulmonary fibrosis in <scp>A</scp>ustralia and <scp>N</scp>ew Zealand: <scp>A</scp> position statement from the <scp>T</scp>horacic <scp>S</scp>ociety of <scp>A</scp>ustralia and <scp>N</scp>ew <scp>Z</scp>ealand and the <scp>L</scp>ung <scp>F</scp>oundation <scp>A</scp>ustralia

Bosentan in Pulmonary Hypertension Associated with Fibrotic Idiopathic Interstitial Pneumonia

The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease